BRSYF Quote, Financials, Valuation and Earnings

Compugen Ltd. has a net margin of 11.59% compared to Brainsway Ltd.'s net margin of -369.06%. Brainsway Ltd.'s return on equity of 10.13% beat Compugen Ltd.'s return on equity of -51.8%.

Brainsway Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 313.91%. Given that Compugen Ltd. has higher upside potential than Brainsway Ltd., analysts believe Compugen Ltd. is more attractive than Brainsway Ltd..

Brainsway Ltd. has a beta of 19.655, which suggesting that the stock is 1865.521% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.

Brainsway Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainsway Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.

Brainsway Ltd. quarterly revenues are $13.5M, which are larger than Compugen Ltd. quarterly revenues of $1.9M. Brainsway Ltd.'s net income of $1.6M is higher than Compugen Ltd.'s net income of -$7M. Notably, Brainsway Ltd.'s price-to-earnings ratio is 54.52x while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainsway Ltd. is 6.55x versus 20.17x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Nasus Pharma has a net margin of 11.59% compared to Brainsway Ltd.'s net margin of --. Brainsway Ltd.'s return on equity of 10.13% beat Nasus Pharma's return on equity of --.

Brainsway Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Brainsway Ltd. has higher upside potential than Nasus Pharma, analysts believe Brainsway Ltd. is more attractive than Nasus Pharma.

Brainsway Ltd. has a beta of 19.655, which suggesting that the stock is 1865.521% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Brainsway Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainsway Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.

Brainsway Ltd. quarterly revenues are $13.5M, which are larger than Nasus Pharma quarterly revenues of --. Brainsway Ltd.'s net income of $1.6M is higher than Nasus Pharma's net income of --. Notably, Brainsway Ltd.'s price-to-earnings ratio is 54.52x while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainsway Ltd. is 6.55x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.

BiomX, Inc. has a net margin of 11.59% compared to Brainsway Ltd.'s net margin of --. Brainsway Ltd.'s return on equity of 10.13% beat BiomX, Inc.'s return on equity of -160.84%.

Brainsway Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 7617.6%. Given that BiomX, Inc. has higher upside potential than Brainsway Ltd., analysts believe BiomX, Inc. is more attractive than Brainsway Ltd..

Brainsway Ltd. has a beta of 19.655, which suggesting that the stock is 1865.521% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.

Brainsway Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brainsway Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.

Brainsway Ltd. quarterly revenues are $13.5M, which are larger than BiomX, Inc. quarterly revenues of --. Brainsway Ltd.'s net income of $1.6M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Brainsway Ltd.'s price-to-earnings ratio is 54.52x while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brainsway Ltd. is 6.55x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.